In one study, a patient developed PTCL secondary to treatment with a checkpoint inhibitor, possibly because PD-1 could also act as a tumor suppressor in T-cell lymphomas [111]. This evidence concerns the gene PDCD1 and mature T-cell and NK-cell non-Hodgkin lymphoma.